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Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a
high drug dose. Partial inhibition of multiple components in the same oncogenic signalling
pathway may add up to complete pathway inhibition, while decreasing the selective pressure
on each component to acquire a resistance mutation. We report here testing of this Multiple
Low Dose (MLD) therapy model in EGFRmutant NSCLC. We show that as little as 20% of the
individual effective drug doses is sufficient to completely block MAPK signalling and pro-
liferation when used in 3D (RAF+MEK+ ERK) or 4D (EGFR+ RAF+MEK+ ERK) inhibitor
combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not
develop resistance. Using several animal models, we find durable responses to MLD therapy
without associated toxicity. Our data support the notion that MLD therapy could deliver
clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor
therapy.
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Inhibition of signalling pathways that are activated by onco-genic mutations elicit therapeutic responses due to “addiction”of the cancer to the activated pathway1. However, in advanced
cancers, development of resistance is practically inevitable due to
secondary mutations that restore signalling through the drug-
inhibited pathway. Such acquired resistance mutations affect
either the drug target itself or components that act upstream,
downstream or parallel to the activated signalling component2,3.
In BRAF mutant melanoma and non-small cell lung cancer
(NSCLC), inhibition of two components of the same oncogenic
pathway (BRAF+MEK, referred to as “vertical targeting”) has
been shown to provide more lasting clinical benefit compared to
inhibition of only BRAF4,5. More recently, both clinical6,7 and
pre-clinical8 studies have shown that inhibition of three compo-
nents of the same oncogenic pathway further increases ther-
apeutic benefit. In these scenarios the drugs are usually
administered at maximum tolerated dose (MTD). The increase in
the number of drugs being used in combination is often
accompanied by an increase in toxicity and to this date virtually
no studies have been done to assess the efficacy of using drugs
below-MTD. In a preclinical model, multiple drugs used at low
dose also demonstrated promising activity in ovarian clear cell
carcinoma9. In this study, we explore the use of a Multiple Low
Dose (MLD) strategy in EGFR mutant NSCLC. In this approach,
multiple drugs that act in the same oncogenic signalling pathway
are combined at low concentration. We hypothesised that this
might add up to complete pathway inhibition without causing
prohibitive toxicity. Further, by using low drug concentrations,
the pressure exerted on each node of the pathway should greatly
diminish, reducing the selective pressure on each node and
therefore diminishing the chances of acquiring resistance.
Results
MLD therapy blocks MAPK pathway and proliferation in PC9
cells. The mechanisms of resistance to EGFR inhibition (stan-
dard-of-care) in EGFR mutant NSCLC are well understood. We
therefore compared the efficacy of MLD therapy to standard-of-
care MTD therapies in this indication. We used PC9 NSCLC cells,
which harbour an activating mutation in the gene encoding
EGFR10. We used four drugs, each inhibiting a different node in
the MAPK pathway: gefitinib (EGFR inhibitor), LY3009120 (pan-
RAF inhibitor11), trametinib (MEK inhibitor) and SCH772984
(ERK inhibitor12), as shown schematically in Fig. 1a. We estab-
lished dose-response curves for each of the four drugs using 5-day
culture assays (Fig. 1b). From these data, we inferred for all 4
inhibitors the IC20 dose, i.e., a drug concentration that inhibits
cell viability by 20%—henceforth referred as Low Dose (LD). To
assess the efficacy of the MLD strategy we then tested the impact
of all possible drug combinations of the 4 drugs at LD on cell
viability (assessed by CellTiter-Blue® assay), on cell proliferation
(assessed by long-term colony formation assay) and on pathway
activity (measured by p-RSK levels13 using Western Blotting)
(Fig. 1c-e). The expected viability and the synergy scores were
calculated using the Bliss independence model14. We found that
PC9 cells treated with the single drugs at low dose were only
minimally affected, as expected. However, some of the drug
combinations showed a striking combination effect, much higher
than expected based on drug additivity. In particular, the com-
bination of RAF+MEK+ ERK inhibitors at low dose (hence-
forth called 3D combination) and the combination of EGFR+
RAF+MEK+ ERK inhibitors at low dose (henceforth called 4D
combination) showed an almost complete inhibition of cell via-
bility and proliferation, along with a complete blockade of MAPK
pathway signalling. Due to these notable findings we pursued the
MLD study focusing on the 3D and 4D combinations. To address
if we could further reduce the drug concentrations, we diluted the
4D combination. When the drugs were reduced to half of the IC20
concentrations, the 4D combination was no longer able to achieve
complete inhibition of proliferation and was similarly unable to
mediate complete MAPK pathway inhibition, indicating that
there is a threshold that limits efficacy (Supplementary Fig. 1a, b).
Based on this, we continued our MLD studies using the IC20
concentrations as “Low Dose”. To make sure our findings were
not drug-specific, we tested the MLD approach using different
inhibitors for each of the nodes in the MAPK pathway (erlotinib
as EGFRi, BGB-283 as RAFi, selumetinib as MEKi and LY-
3214996 as ERKi). Supplementary Fig. 1c, d show that we
obtained essentially the same effect with these drugs in 3D and
4D combinations. This, together with the notion that each drug is
used at low dose, makes it very unlikely that off target effects of
the four drugs are responsible for the observed effects.
MLD therapy minimises therapeutic resistance. Next, we tested
how MLD therapy compares to standard-of-care high dose
therapy in terms of resistance development. To mimic high dose
therapy, we treated PC9 cells with a concentration of EGFR
inhibitor gefitinib that inhibited cell viability by ~99% in a 5-day
culture assay – henceforth referred as High Dose (HD). We found
that 3D and 4D combinations inhibit cell proliferation and induce
apoptosis at comparable levels to cells treated with HD of gefi-
tinib (Fig. 2a and Supplementary Fig. 2a, b). The level of pathway
inhibition is also similar between cells treated with 3D and 4D
combinations and HD of gefitinib (Fig. 2d). In addition, we
performed RNA-Seq transcriptome analyses in cells treated with
4D combination (Supplementary Fig. 2c, d). These data showed
that 4D combo treated cells displayed a significant down-
regulation of MYC and E2F target genes, as well as cell cycle
genes. Moreover, MAPK activity markers15 were significantly
downregulated and several pro-apoptotic genes were found to be
upregulated, while anti-apoptotic genes were downregulated. To
study how MLD therapy compares to HD therapy regarding
resistance, we treated PC9 cells with 3D or 4D combinations and
with HD of gefitinib or osimertinib for one month (Fig. 2b). As
seen by others previously16,17, cells treated with HD of gefitinib or
osimertinib quickly developed resistance, but the cells treated
with 3D or 4D combinations did not. In addition, we treated PC9
cells for 16 days with high dose of gefitinib or with 3D or with 4D
MLD combinations; we then either removed the drugs, continued
to treat with the original drug, or treated with 4D MLD combi-
nation for another 16 days (Supplementary Fig. 2e). We observed
resistant colonies after 32 days of gefitinib treatment, but not in
the cells treated with 3D or 4D combinations. Apparently, 16 day-
treatment with 3D or 4D combinations had killed all cells, as
continued culturing for another 16 days in media without drugs
did not yield any colonies. Importantly, PC9 cells that had
developed resistance to high dose EGFR inhibitor, were still
responsive to 4D MLD combination. This striking result indicates
that EGFR inhibitor-resistant cells remain sensitive to 3D and 4D
combinations. This suggests that MLD therapy might be an
option for patients having developed resistance to standard-of-
care EGFR inhibitor therapy.
MLD therapy is effective in EGFRi-resistant PC9 cells. To study
further if EGFRi-resistant cells are indeed sensitive to 3D and 4D
combinations, we generated PC9 cells resistant to clinically-used
EGFR inhibitors. We cultured PC9 cells in the presence of gefi-
tinib (PC9-GR) or osimertinib (PC9-OR) until cells were no
longer responsive to the inhibitors (see methods). We performed
exome sequencing of the two resistant cell populations to gain
insight into the mechanisms of acquired resistance. These data
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showed acquisition of the well-known T790M mutation in the
PC9-GR cells and a number of mutations in the PC9-OR cells,
none of which has been previously associated with resistance to
osimertinib (Supplementary Table 2). We then tested the sensi-
tivity of the resistant lines to 3D and 4D combinations. In both
resistant cell populations, we saw an almost complete inhibition
of cell viability after only 4 days of MLD therapy treatment and a
complete MAPK pathway signalling blockade (Fig. 2c, d).
MLD therapy is effective in multiple tumour models. We then
tested if the MLD strategy would also be effective in additional
in vitro tumour models. After low dose determination (Supple-
mentary Fig. 3a-c and Supplementary Table 1) we tested the MLD
strategy in patient-derived (colorectal and NSCLC) organoids.
Treatment with 3D and 4D combinations resulted in a major
reduction in cell viability (Fig. 3a). In addition, we tested 6 dif-
ferent MAPK pathway addicted cell lines: HCC827 and H3255
(EGFR mutant lung cancer), H2228 and H3122 (EML4-ALK
translocated lung cancer, in which EGFRi was replaced with ALK
inhibitor crizotinib in the 4D combination), DiFi and Lim1215
(EGFR dependent colorectal cancer) and in 2 different PI3K
pathway addicted cell lines: SKBR3 and HCC1954 (HER2
amplified breast cancer, in which 4D combination consisted of
HER2, PI3K, AKT and mTOR inhibitors). When treated with 4D
combination, proliferation of all cell lines was inhibited, regard-
less of the tumour type/driver/genotype, pointing towards a broad
applicability of the MLD treatment strategy (Supplementary
Fig. 3d).
MLD therapy is tolerated by non-tumorigenic cell lines. One of
the major concerns when using multiple drugs in combination is
the possible toxicity to normal tissues18. To test the effect of the
MLD strategy on “normal” (non-tumorigenic) cell lines we used
primary human BJ (fibroblast) and RPE1 (retinal pigment epi-
thelium) cells. Upon 3D and 4D MLD drug combination treat-
ment, cell viability was reduced, but to a much lesser extent than
in cancer cells. This indicates that the MLD strategy might be
tolerated by normal tissues (Fig. 3b). Since the MAPK pathway is
rich in cross-talk and feedback control circuits19,20, we also tested
how a pulse of signalling through the EGFR pathway would be
affected by 3D or 4D MLD treatment. We serum-starved BJ cells
overnight and then incubated with 3D or 4D MLD drug com-
binations for 2 h. After this, cells were stimulated with 100 ng/mL
of EGF in the presence of 3D or 4D drug combinations. Twenty
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Fig. 1 Multiple low dose therapy blocks MAPK pathway and proliferation in PC9 cells. a Schematic of the Multiple Low Dose (MLD) efficacy
determination. After plating, cells are treated with increasing drug concentrations. Four days later cell viability is measured and the low dose (LD) is
assessed. At last, the efficacy of all the possible combinations at LD is determined. b Dose-response curves of EGFR, RAF, MEK and ERK inhibitors in PC9
cells. PC9 cells were cultured with increasing concentrations of EGFRi Gefitinib, RAFi LY3009120, MEKi Trametinib or ERKi SCH772984 for 4 days, after
which cell viability was measured using CellTiter-Blue®. Standard deviation (SD) from 3 biologically independent replicates (each with 3 technical
replicates) is plotted. Low doses (IC20s) were then determined: gefitinib=7 nM, LY3009120= 250 nM, 292 trametinib= 8 nM and SCH772984=
250 nM. c–e Determination of the efficacy of all the possible combinations of EGFR, RAF, MEK and ERK inhibitors at LD in PC9 cells. PC9 cells were
cultured with all possible drug combinations of EGFR, RAF, MEK and ERK inhibitors at the low doses determined in b. In c cell viability from 3 biologically
independent replicates (each with at least 3 technical replicates) was measured by CellTiter-Blue® assay after 4 days of treatment; In black the observed
experimental viability; In dark-grey the expected viability and in light-grey the synergy scores, calculated using the Bliss independence model, are plotted. In
d cells were treated for 10 days, after which plates were stained and scanned; A representative image from the 3 biologically independent replicates
performed is displayed. In e protein for western blotting was harvested after 24 h of treatment; The level of pathway inhibition was determined by
examining pRSK protein levels in the western blot. Tubulin was used as loading control.
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minutes after EGF stimulation, a significant amount of p-RSK
was detected, which was no longer detected at 4 h post EGF sti-
mulation (Fig. 4c). These data suggest that the efficient inhibition
of MAPK signalling exerted by 3D and 4D MLD treatment is the
result of an effect of these drugs on homoeostatic feedback/cross-
talk signalling19,21, as pulsatile signalling through the MAPK
pathway seems to be much less affected than persistent signalling
through an oncogene-activated MAPK pathway.
MLD therapy induces tumour regression without toxicity
in vivo. To address if the MLD strategy is effective in vivo, we
used patient derived xenograft (PDX) tumours from four differ-
ent patients who had developed resistance to first-line or second-
line therapy with EGFR inhibitors erlotinib or osimertinib22 in
the clinic by acquiring EGFR T790M mutation, KRAS mutation
or MET amplification (Supplementary Table 3). For the in vivo
studies we defined LD as 20% (for gefitinib and trametinib) and
30% (for LY3009120 and SCH772984—due to the shorter half-
lives) of the published maximum tolerated dose (MTD) in mice
for each of the individual drugs11,12,23,24. Osimertinib-resistant
PDX-1 was implanted subcutaneously and orthotopically in the
lungs. In both models, treatment with 3D or 4D combination
resulted in a reduction in tumour volume, without associated
toxicity (Fig. 4a-d). Interestingly however, treatment with 4D
combo was slightly more effective than 3D combo. Due to this
finding we focused the in vivo studies that followed on the 4D
combination. In all PDX models tested we observed similar
results to PDX-1, i.e., a reduction in tumour volume, without
significant toxicity (Fig. 4e, f and Supplementary Fig. 4e). In
addition, in gefitinib-resistant models PDX-2 and PDX-3 we
tested if it would be possible to acquire resistance to the 4D MLD
combination therapy during a drug holiday. In both PDX models,
re-starting of 4D MLD therapy after a drug holiday resulted in a
second response to the drug combination, indicating that overt
resistance had not developed in vivo (Fig. 4e, f).
We also implanted PC9 cells in nude mice and treated them
















































































































































































































































































































































































Fig. 2 MLD therapy minimises therapeutic resistance and is effective in EGFRi-resistant PC9 cells. a MLD therapy abrogates cell proliferation and
induces apoptosis in PC9 cells. PC9 cells were plated and incubated overnight to allow attachment to the plate. Cells were then treated with DMSO, with
EGFR, RAF, MEK, ERK inhibitors at low dose, with 3D Combo (RAF+MEK+ ERK inhibitors at LD) or with 4D Combo (EGFR+ RAF+MEK+ ERK
inhibitors at LD) and placed in the IncuCyte®. Confluence (left) and caspase 3/7 activation (right) over time was measured by the IncuCyte®. Standard
error of the mean (SEM) from 3 replicates is plotted. b MLD therapy prevents the acquisition of drug resistance in PC9 cells. PC9 cells were cultured with
DMSO, with EGFR, RAF, MEK and ERK inhibitors at low dose (for 7 days) and with high dose (HD) of Osimertinib (200 nM), HD of Gefitinib (280 nM) and
with 3D and 4D Combinations (for 1 month), after which plates were stained and scanned; A representative image from 3 biologically independent
replicates is displayed. c EGFRi-resistant PC9 cells remain sensitive to MLD therapy. PC9, PC9-OR (Osimertinib-resistant) and PC9-GR (Gefitinib-
resistant) cells (see methods) were cultured with DMSO, with low doses of EGFR, RAF, MEK or ERK inhibitors, with 3D or 4D combinations or with HD of
Gefitinib or Osimertinib for 4 days, after which cell viability was measured using CellTiter-Blue®. Standard deviation (SD) from 3 biologically independent
replicates is plotted. d MLD therapy blocks MAPK pathway in EGFRi-resistant PC9 cells. PC9, PC9-OR and PC9-GR cells were cultured with DMSO, HD of
Osimertinib, HD of Gefitinib or with 3D or 4D combinations. Protein for western blotting was harvested after 24 h of treatment; The level of pathway
inhibition was measured by examining pERK and pRSK protein levels and the level of EGFR inhibition was measured by examining pEGFR protein levels in
the western blot. Tubulin and Vinculin were used as loading control.
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individually at low dose and with 4D combination. The use of low
dose regimens was inadequate to suppress PC9 tumour growth
when used as single agents, but when used in combination we
observed a sustained reduction in the tumour volume of PC9
xenografts over a period of 70 days, which was associated with an
extended survival (Supplementary Fig. 4a, b). These observations
are also supported by immunohistochemical staining of the
tumours, which show decreased Ki67 (a proliferation marker)
and pERK (MAPK activation) levels in the tumours treated with
4D combination (Fig. 4g). Significantly, mice treated with 4D
combination did not show any significant signs of toxicity,
assessed by the weight of the mice over time and by the
morphology of the GI tract and bone marrow (Supplementary
Figs. 4c, f). In the clinic, the T790M mutation is already present
(at very low percentages) in the majority of the tumours before
undergoing anti-EGFR treatment25,26. To mimic this scenario, we
implanted in nude mice a mix of PC9 cells and PC9-GR cells
(which are T790M positive) in a 9:1 ratio, respectively. Mice were
treated with vehicle, with MTD of gefitinib and with 4D
combination. Treatment with MTD of gefitinib resulted in a
quick reduction of tumour volume which was followed by
outgrowth of resistant cells, unlike the mice treated with 4D
combination, where a sustained tumour control was observed
(Supplementary Fig. 4d).
Despite the significant tumour regressions observed in the
in vivo experiments none of the mice were fully cured, unlike in
the in vitro data where all the cells were killed by the 3D or 4D
combinations. To study why this is the case we studied the
pharmacokinetics and pharmacodynamics of the four drugs
in vivo over time. We found that drug plasma concentrations of
gefitinib and trametinib dropped relatively slowly (T1/2 8 h), but
the pan-RAF and ERK inhibitors were less stable in plasma (T1/2
of 5 and 4 h, respectively). A similar difference was seen for intra-
tumoural drug concentrations (Supplementary Figs. 5a, b).
Consistent with this, we observed a complete inhibition of pRSK
in tumour biopsies 2 h after 4D combination drug administration,
which progressively decreased after 8 and 24 h (Supplementary
Fig. 5c). These data indicate that, unlike in the in vitro
experiments, two of the four drugs were not present at a
significant concentration during at least 12 h of the 24-h
treatment cycle. As a result of this, a sustained MAPK pathway
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Fig. 3 MLD therapy is effective in patient-derived organoids and is tolerated by normal cell lines. a MLD therapy is effective in several colorectal and
lung cancer patient-derived organoids. Organoids were cultured with DMSO, with EGFR, RAF, MEK and ERK inhibitors at LD and with 3D and 4D combos.
After 5 days of drug treatment cell viability was measured using CellTiter-Glo®. Standard deviation (SD) from 3 biologically independent replicates is
plotted. b Cell viability of normal cells is much less affected by MLD therapy than tumour cells. BJ and RPE1 cells were treated with DMSO, with EGFR, RAF,
MEK and ERK inhibitors at low and high doses and with 3D and 4D Combos (using the LD and HD concentrations determined for PC9 cells). After 4 days
of drug treatment cell viability was measured. SD from 3 replicates is plotted. cMLD therapy allows pulsed signaling in normal cells. BJ cells, after overnight
starvation, were treated with the indicated inhibitors/concentrations for 2 h, after which EGF (100 ng/mL) was added. Cells were harvested before, 20min
and 4 h after EGF stimulation. The level of pathway inhibition was measured by examining pERK and pRSK protein levels. The level of EGFR inhibition was
measured by examining pEGFR protein levels in the western blot. Tubulin was used as loading control.
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didn’t achieve full tumour regressions. We tested this hypothesis
in vitro, by removing RAF and ERK inhibitors from the treatment
for approximately 8 h every day. We found that, as hypothesised,
when the drugs in the 3D or 4D combination were not present
continuously the MLD therapy became less effective (Supple-
mentary Fig. 5d). Finally, we tested whether there was any drug-
drug interaction by measuring the half-lives of the drugs when
given alone or in combination (Supplementary Fig. 5e). Overall,
there is not any apparent drug-drug interaction, except for
LY3009120, for which the half-life increases when given in the
4D Combo.
Discussion
We report here that treatment of EGFR mutant NSCLCs with
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Fig. 4 MLD therapy induces tumour regression without toxicity in vivo. a–f Patient derived xenografts (PDX) are sensitive to MLD therapy. PDX tumours
(see Supplementary Table 3) were implanted subcutaneously (a, e, f) or orthotopically in the lungs (c) of Crl:NU-Foxn1nu mice. PDX1 was implanted both
subcutaneously (a) and orthotopically in the lungs (c). We defined the in vivo LD as 20–30% of the MTD for each of the individual drugs–gefitinib
(10mg/kg), LY3009120 (6mg/kg), trametinib (0.5 mg/kg) and SCH772984 (15mg/kg). In a–d after tumour establishment, mice were treated 5 days/
week with vehicle, with osimertinib (5mg/kg) and with 3D or with 4D Combos for 26 days, after which mice were sacrificed. In a tumour volume
percentages ±SEM is shown, in c tumour size (mm3) at sacrifice ±SEM is shown and in b and d the mice weight percentages ± SEM is shown. e After
tumour establishment, mice were treated 5 days/week with Vehicle (N= 3), with gefitinib (80mg/kg) (N= 4) or with 4D Combo for 6 weeks (group A,
N= 3) or with 4D Combo for 8 weeks (group B, N= 3). Mice treated with vehicle and gefitinib were sacrificed when tumours reached ~2000mm3. After
6 weeks, Group A was taken off treatment and mice were sacrificed when tumours reached ~2000mm3. After 8 weeks Group B was taken off treatment
and was given 3 weeks of drug holiday. Mice were then treated for another 2 weeks with 4D combo, after which they were sacrificed. Tumour volume
percentages ±SEM is shown. f After tumour establishment, mice were treated 5 days/week with vehicle (N= 4), with gefitinib (80mg/kg) (N= 5) or with
4D Combo (N= 9) for 4 weeks, after which mice were sacrificed, except for 4 animals from the 4D Combo group. These 4 mice were spared and were
given 3 weeks drug holiday (4D Combo DH group), followed by another 3 weeks of treatment, after which they were sacrificed. Tumour volume
percentages ±SEM is shown. g H&E, Ki67 and pERK stainings from tumour sections of PC9 xenografts. A representative staining image from each cohort
(N≥ 6) is displayed. Scale bars 100 µm. h Schematic representation of the MLD therapy for the treatment of EGFR mutant NSCLC.
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resistance, without associated toxicity. As such, our data challenge
the common paradigm that patients should be treated with the
MTD of a targeted agent. Our data are consistent with a model in
which diffuse inhibition of an oncogenic pathway at multiple
nodes reduces selective pressure on each of the nodes to mutate
and thereby increase response time (Fig. 4h). Our findings also
challenge the current model for MAPK pathway signalling, which
postulates that the MAPK kinase cascade functions to amplify
signals. Such amplification cascade model is clearly at odds with
the data obtained here in which a very partial inhibition of each
of 4 nodes in this cascade adds up to complete pathway inhibi-
tion. Further mechanistic studies are required to better under-
stand the efficacy of the MLD strategy.
Importantly, we show that tumours having the most common
mechanisms of clinically-observed resistance to high dose stan-
dard of care EGFR inhibitors still respond to MLD therapy.
Therefore, MLD treatment strategy appears especially promising
for patients that have already developed resistance to all clinically
used EGFR inhibitors, including osimertinib. In such resistant
tumours, multiple metastases may be present having different
resistance mutations. In this study we have shown that MLD
therapy is effective in PDX models having diverse EGFR inhibitor
resistance mechanisms, including EGFR T790M mutation, KRAS
mutation, MET amplification and even SCLC transformation,
highlighting that MLD therapy could apply to a diverse range of
EGFR TKI resistant tumours. However, not all the resistance
mechanisms have been tested and it is possible that some might
not respond to MLD therapy. Indeed, in clinical practice, an MLD
treatment strategy can only be tested in patients having developed
resistance to standard-of-care EGFR inhibitors. We find in PDX
models that 4D MLD is consistently somewhat better than 3D
MLD, which may relate to the notion that not all EGFR alleles in
the tumour may have acquired resistance mutations to the EGFR
inhibitor therapy. Furthermore, it will be important to maintain
osimertinib in an experimental MLD therapy trial, as this drug
crosses the blood-brain barrier, and such late-stage patients may
have (latent) brain metastases. We therefore suggest that clinical
testing of the MLD strategy should include osimertinib.
While we never observed development of resistance to MLD
therapy in vivo, even after long drug exposure, we did not achieve
complete tumour regressions. This is most likely due to the short
half-lives of the RAF and ERK inhibitors used in this study, which
resulted in a situation in which we did not achieve a continuous
pathway blockade. This may be improved by using continuous
release formulations of these drugs, or by using drugs with longer
half-lives.
The MLD therapy described here is fundamentally different
from metronomic chemotherapy27,28. In this latter scenario, low
doses of chemotherapy are given at high frequency with the aim
to suppress division of endothelial cells of the tumour vasculature.
In the present MLD schedule, we target the MAPK pathway of
the tumour itself, as growth inhibition in all cases parallels
inhibition of the MAPK pathway (as judged by pRSK). Three-
drug combinations given at MTD have been used before in pre-
clinical8 and clinical studies6,7 for BRAFV600E mutant tumours,
showing clear therapeutic benefits, but such regimen have an
associated cost of toxicity.
The lack of significant toxicity of the MLD therapy in mice
may be explained by the fundamentally different nature of MAPK
pathway signalling between normal and EGFR mutant cancer
cells. In the former, signalling is transiently activated when
growth factors are present. In the latter, oncogenic mutations
result in persistent activation of the pathway. Importantly, we
show here that transient signalling in normal cells is, at least
initially, not interrupted by MLD treatment (Fig. 3c). This may
explain why long-term exposure of mice to MLD treatment is
without major toxicity, as judged by lack of weight loss and lack
of toxicity to gut epithelium and bone marrow. However, mice
and human are fundamentally different with respect to drug
toxicity. Especially skin toxicity following MAPK inhibition
therapy is often underestimated in mice. Therefore, only a phase I
clinical trial will be able to fully assess the toxicity of this strategy
in humans.
Extrapolation of dose from animals to humans based only on
mg/kg conversion is difficult, since body surface area and dif-
ferences in pharmacokinetics should also be taken into con-
sideration. To convert the animal dose in mg/kg to human
equivalent doses (HED) in mg/kg, it is recommended to divide by
12.329. If we estimate the HED based on the low-doses used in
our in vivo experiments for Gefitinib and Trametinib (where
dosing in humans is known) using this approach then Gefitinib
(10 mg/kg in mice) corresponds to 57 mg once daily in patients,
which is approximately one quarter of the dose used in patients
(250 mg qd). And Trametinib (0.5 mg/kg in mice) corresponds to
2,8 mg once daily in patients, which is a bit higher than the dose
used in patients (2 mg qd). However, we also we performed an
in vivo experiment using lower concentrations of Gefitinib (1 mg/
kg) and Trametinib (0.1 mg/kg) (Supplementary Fig. 4d). These
drug concentrations correspond to 2,5% of the human daily
dose for gefitinib and 28% of the daily human dose of trametinib,
using the calculation method of Nair mentioned above. These
data indicate that with these further reduced concentrations of
Gefitinib and Trametinib we still have a significant anti-tumor
effect in vivo. Due to the difficulty in translating drug doses from
mice to human we feel that only a well-designed phase 1 trial can
help assess the potential clinical utility of the MLD strategy
proposed here.
Even though we focused mostly on EGFR mutant NSCLC, we
have also shown that the MLD strategy can potentially be effec-
tive in other tumour types. Overall, our findings challenge the
current paradigm of using the maximum tolerated dose of single
targeted cancer drugs and suggest that, instead, it might be
more beneficial to use a combination of multiple drugs that target
the oncogenically activated pathway using sub-optimal drug
concentrations.
Methods
Cell lines culture and drug-response assays. The PC9 cell line was obtained
from ATCC. PC9OR (osimertinib-resistant) and PC9GR (gefitinib-resistant) cells
were made by continuous (2 months) drug exposure of PC9 cells to 1 µM osi-
mertinib (AZD9291) and to 2 µM gefitinib, respectively. Exome sequencing was
performed to determine if any de novo genetic alterations had occurred (Supple-
mentary Table 2). The HCC827, H3255, H3122, H2228, SKBR3, HCC1954, BJ and
RPE1 cell lines were obtained from ATCC. And DiFi and Lim1215 cell lines were a
gift from A. Bardelli (Torino, Italy). BJ and RPE1 cells were cultured in DMEM
(Gibco 41966029). SKBR3 and HCC1954 which were cultured in DMEM/F-12
medium (Gibco 31331028). All the other cell lines were cultured in RPMI medium
(Gibco 21875034). All the cell lines media were supplemented with 10% FBS
(Serana), 1% penicillin/streptomycin (Gibco 15140122) and 2 mM L-glutamine
(Gibco 25030024). All cell lines were cultured at 37 °C and with 5% CO2. All cell
lines were validated by STR profiling and mycoplasma tests were performed every
2–3 months.
All drug-response assays were performed in triplicate, using black-walled 384-
well plates (Greiner 781091). Cells were plated at the optimal seeding density
(Supplementary Table 1) and incubated for approximately 24 h to allow
attachment to the plate. Drugs were then added to the plates using the Tecan
D300e digital dispenser. 10 µM phenylarsine oxide was used as positive control (0%
cell viability) and DMSO was used as negative control (100% cell viability). Four
days later, culture medium was removed and CellTiter-Blue (Promega G8081) was
added to the plates. After 1–4 h incubation, measurements were performed
according to manufacturer’s instructions using the EnVision (Perkin Elmer).
Organoid culture and drug-response assays. Colorectal (CRC) and non-small
cell lung cancer (NSCLC) organoids were established and handled as previously
described30. All drug-response assays were performed in replicate, each by inde-
pendent researchers. PDOs were mechanically and enzymatically dissociated into
single cells, pipetted through a 40 µM cell strainer, and re-plated to allow for
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organoids formation. At day 4 PDOs were collected, Cultrex was removed by
incubation of the cell pellet in 1 mg/mL dispase II (Sigma D4693) for 15 min.
Whole organoids were counted using a hemocytometer and trypan blue. PDOs
were resuspended in 1:3 Advanced Dulbecco’s Modified Eagles Medium with
Nutrient Mixture F-12 Hams (Ad-DF) (Invitrogen 12634), supplemented with 1%
penicillin/streptomycin (Invitrogen 15140122), 1% HEPES (Invitrogen 15630056)
and 1% GlutaMAX (Invitrogen 35050) (Ad-DF+++):Cultrex at a concentration of
20 organoids/µL. Five µl/well was dispensed in clear-bottomed, white-walled 96-
well plates (Greiner Bio-One 655098) and overlaid with 200 µL CRC or NSCLC
culture medium. We generated 10-step dose response curves using the Tecan
D300e digital dispenser, interpolated IC20 values and re-screened organoids in
presence of a range of concentration around the IC20 of each drug separately and in
3D and 4D Combos. In addition, we re-performed the dose-response curves to
control for variation between experiments. Read-out was performed at day 10 in
the positive control (10 µM phenylarsine oxide), negative control (DMSO), and the
drug-treated wells. Quantification of cell viability was done by replacing the
CRC medium with 50 µL Cell-TiterGlo 3D (Promega G9681) mixed with 50 µL
Ad-F+++. Measurements were performed according to manufacturer’s instruc-
tions on an Infinite 200 Pro plate reader (Tecan Life Sciences) with an integration
time of 100 ms.
Compounds, reagents and antibodies. Gefitinib (100140), LY3009120 (206161),
trametinib (201458), SCH772984 (406578), osimertinib (206426), crizotinib
(202222), lapatinib (100946), BKM120 (204690), MK2206 (201913) and AZD8055
(200312) were purchased from MedKoo Biosciences. Erlotinib (S7786), BGB-283
(S7926), selumetinib (S1008) and LY-3214996 (S8534) were purchased from Sell-
eckchem. Annexin V-FITC Apoptosis Staining Detection Kit was purchased from
Abcam (ab14085).
Antibodies against Tubulin (T9026) and Vinculin (V9131) were purchased
from Sigma; antibodies against EGFR (4267), pERK (4377), ERK (9102) and RSK
(8408) were purchased from Cell Signalling; antibody against pRSK (04-419) was
purchased from Millipore; antibody against pEGFR (ab5644) was purchased from
Abcam. Secondary antibodies Goat Anti-Rabbit IgG (H+ L)-HRP Conjugate
(1706515) and Goat Anti-Mouse IgG (H+ L)-HRP Conjugate (1706516) were
purchased from Bio Rad.
Colony formation and IncuCyte cell proliferation assays. Cells were seeded in
the appropriate density (Supplementary Table 1) in 6-well plates. Cells were
incubated for approximately 24 h to allow attachment to the plates, after which
drugs were added to the cells using the Tecan D300e digital dispenser as indicated.
The culture media/drugs were refreshed every 3/4 days. When control wells
(DMSO) were confluent (unless otherwise stated in the text) cells were fixed using a
solution of 2% formaldehyde (Millipore 104002) diluted in phosphate-buffered
saline (PBS). Two hours later, they were stained, using a solution of 0.1% crystal
violet (Sigma HT90132) diluted in water. Not more than 10 min later the staining
solution was removed, plates were washed with water left to dry overnight. Finally,
plates were scanned and stored.
For IncuCyte proliferation assays, cells were seeded in 96-well plates and
incubated overnight to allow attachment to the plates. Drugs were added to the
cells using the Tecan D300e digital dispenser. Cells were imaged every 4 h in the
IncuCyte ZOOM (Essen Bioscience). Phase-contrast images were collected and
analysed to detect cell proliferation based on cell confluence. For cell apoptosis,
IncuCyte® Caspase-3/7 green apoptosis assay reagent (Essen Bioscience 4440) was
also added to culture medium and cell apoptosis was analysed based on green
fluorescent staining of apoptotic cells.
Western Blots. After the indicated culture period, cells were washed with chilled
PBS and then lysed with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitors
(Complete (Roche) and phosphatase inhibitor cocktails II and III). Samples were
then centrifuged for 10 min at 14.000 rpm at 4 °C and supernatant was collected.
Protein concentration of the samples was normalised after performing a Bicinch-
oninic Acid (BCA) assay (Pierce BCA, Thermo Scientific), according to the
manufacturer’s instructions.
Protein samples (denatured with DTT followed by 5 min heating at 95 °C) were
then loaded in a 4–12% polyacrylamide gel. Gels were run (SDS-PAGE) for
approximately 60 min at 165 V. Proteins were then transferred from the gel to a
polyvinylidene fluoride (PVDF) membrane, using 330 mA for 90 min.
After the transfer, membranes were placed in blocking solution (5% bovine
serum albumin (BSA) in PBS with 0,1% Tween-20 (PBS-T). Subsequently,
membranes were probed with primary antibody in blocking solution (1:1000) and
left shaking overnight at 4 °C. Membranes were then washed 3 times for 10 min
with PBS-T, followed by 1 h incubation at room temperature with the secondary
antibody (HRP conjugated, 1:10000) in blocking solution. Membranes were again
washed 3 times for 10 min in PBS-T. Finally, a chemiluminescence substrate (ECL,
Bio-Rad) was added to the membranes and the Western Blot was resolved using
the ChemiDoc (Bio-Rad).
Mouse xenografts studies. All animal experiments were approved by the Animal
Ethics Committee of the Netherlands Cancer Institute or by the Animal Ethics
Committee of the Institut Català d’Oncologia and performed in accordance with
institutional, national and European guidelines for Animal Care and Use.
PC9 cell line xenografts: One million PC9 cells were resuspended in PBS and
mixed 1:1 with matrigel (Corning 354230). Cells were injected subcutaneously into
the posterior flanks of 7-week-old immunodeficient BALB/cAnNRj-Foxn1nu mice
(half male and half female; Janvier Laboratories, The Netherlands). Tumour
formation was monitored twice a week. Tumour volume, based on calliper
measurements, was calculated by the modified ellipsoidal formula (tumour volume
= 1/2(length × width2)). When tumours reached a volume of approximately 200
mm3, mice were randomized into the indicated treatment arms. Vehicle, gefitinib,
LY3009120, trametinib, SCH772984 or the combination of the 4 inhibitors were
formulated in DMSO: Kolliphor EL (Sigma 27963): Saline solution, in a ratio of
(1:1:8). Mice were treated 5 days a week (Monday to Friday) at the indicated doses
by intraperitoneal injection.
Patient-derived xenografts (PDX) and orthotopic xenograft (PDOX): Primary
tumours were obtained from Bellvitge Hospital (HUB) and the Catalan Institute of
Oncology (ICO) with approval by the Ethical Committee. Ethical and legal
protection guidelines of human subjects, including informed consent from the
patient to implant the tumour in mice, were followed. PDX-1 was generated from a
lung adenocarcinoma biopsy from a patient who was treated with Erlotinib (first
line), Gefitinib+Capmatinib (second line) and Cisplatin+Pemetrexed (third line).
This tumour has an EGFR mutation (del19) and MET amplification. PDX-2 was
generated from a lung adenocarcinoma biopsy from a patient who was treated with
Erlotinib (first line), Gefitinib+Capmatinib (second line) and Carboplatin
+Gemcitabine and Nivolumab (third line). This tumour has an EGFR mutation
(L858R) and MET amplification. PDX-330 was generated from a lung
adenocarcinoma biopsy of a brain metastasis from a patient who was treated with
Erlotinib (first line) and Osimertinib (second line). PDX-4 was generated from a lung
adenocarcinoma biopsy from a patient who was treated with Afatinib (first line) and
CBDCA+ pemetrexed (second line). This tumour has a germline p53 mutation and
an EGFR mutation (del19). Tumours were isolated and implanted subcutaneously
(or orthotopically, in the lungs, in the case of PDX-3) into Crl:NU-Foxn1nu mice by
following previously reported procedures22,31. In the subcutaneous models, tumour
volume was monitored twice a week by a digital caliper. When tumours reached a
volume of approximately 200–600mm3, mice were randomized into the indicated
treatment arms. In the orthotopic model, tumours were left to grow for 2 weeks,
followed by 26 days of treatment. Vehicle, gefitinib, osimertinib or the 3D and 4D
Combos were formulated in DMSO: Kolliphor EL (Sigma 27963): Saline solution, in
a ratio of (1:1:8). Mice were treated 5 days a week (Monday to Friday) at the
indicated doses by intraperitoneal injection.
In vivo pharmacokinetics and pharmacodynamics studies. Plasma and tumour
samples were assayed by liquid chromatography triple quadrupole mass spectro-
metry (LC-MS/MS) using an API4000 detector (Sciex) for the simultaneous
determination of Gefitinib (MRM: 447.4/128.1), LY3009120 MRM: 425.5/324.2),
Trametinib (616.3/491.2) and SCH772984 (MRM: 588.4/320.2). Gefitinib-d8
(MRM: 455.4/136.3) was used as internal standard. LC separation was achieved
using a Zorbax Extend C18 column (100 × 2.0 mm; ID). Mobile phase A and B
comprised 0.1% formic acid in water and methanol, respectively. The flow rate was
0.4 ml/min and a linear gradient from 20%B to 95%B in 2.5 min, followed by 95%B
for 2 min, followed by re-equilibration at 20%B for 10 min was used for elution.
Sample pre-treatment was accomplished by mixing 5 μL (plasma) or 25 μL (tumour
homogenate) with 30 or 150 μL, respectively, of formic acid in acetonitrile (1+ 99)
containing the internal standard. After centrifugation, the clear supernatant was
diluted 1+ 4 with water and 50 μL was injected into the LC-MS/MS system.
The plasma/tumour samples were harvested at the time points indicated in
Supplementary fig. 5. Blood samples were obtained by tail cut (at 2 h and 8 h time
points) and by cardiac puncture at the 24 h time point. Samples were collected on
ice in tubes containing potassium EDTA as anticoagulant. The tubes were
immediately cooled in melting ice and centrifuged (10 min, 5000×g, 4 °C) to
separate the plasma fraction, which was transferred into clean vials. For the
tumours samples, the mice were sacrificed by cervical dislocation, the tumour was
dissected and frozen at −80 °C. Half of the tumour was then lysed mechanically
with RIPA buffer and lysates were analysed by Western blot. The other half was
weighed and homogenised in 1 mL of ice-cold 1% of BSA in water and stored at
−20 °C until further analysis.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the corresponding author upon request. Full scans of
the gels and blots are available in Supplementary Fig. 7. All the other data supporting the
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